TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7944440
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose arterial infusion group
Study: 7944440
Drug: Repeated one-shot
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated one-shot arterial infusion group
Study: 7944440
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose arterial infusion of 5-FU
Study: 9598255
Drug: Thiopentone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (5 mg.kg‐1)
Study: 9598255
Drug: Thiopentone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone plus Atracurium (5 mg.kg‐1 thiopentone plus 0.05 mg.kg‐1 atracurium)
Study: 7945786
Drug: Balsam of
Normalized name: Balsam of Peru
DrugBank: Balsam of Peru (DB11482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsam of Peru (225 mg)
Study: 28235882
Drug: Pembrolizumab (KEYTRUDA)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (KEYTRUDA) at a dose of 2 mg/kg every 3 weeks by intravenous infusion
Study: 25352527
Drug: treatment-as-usual condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual condition
Study: 19687393
Drug: High-frequency treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency treatment
Study: 19687393
Drug: Electrocautery treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocautery treatment
Study: 15321290
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with intermittent injection through the epidural needle
Study: 19799020
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) treatment
Study: 20016179
Drug: Standard semiannual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard semiannual application of fluoride varnish (one active and two placebo treatments every 6 months)
Study: 15200736
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of sumatriptan 50 mg
Study: 15200736
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of sumatriptan 100 mg
Study: 1652976
Drug: LHRH agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonists and tamoxifen
Study: 22172901
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant radiotherapy (HD-ART) with androgen deprivation therapy (ADT)
Study: 22172901
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant radiotherapy (HD-ART) without androgen deprivation therapy (ADT)
Study: 22172901
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant radiotherapy (HD-ART)
Study: 12672309
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microg daily for adults, 200 microg for children younger than 11 years)
Study: 8675160
Drug: [(13)C 3‐methyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(13)C 3‐methyl] caffeine breath test (CBT) administered to 20 patients at a dosage of 2 mg/kg
Study: 8675160
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available CBT kit with a constant 200-mg dose administered to 17 patients
Study: 8675160
Drug: Standardized-dose CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized-dose CBT
Study: 1562332
Drug: Benzonatate 200
Normalized name: benzonatate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzonatate 200 mg topically for oropharyngeal anesthesia
Study: 1562332
Drug: Bilateral superior
Normalized name: Sus scrofa superior gastric plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superior laryngeal nerve blocks (total 8 ml of 1% lidocaine) and 2 ml of 20% benzocaine orally
Study: 30958332
Drug: Platelet-rich fibrin
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich fibrin (PRF) injection
Study: 30219436
Drug: Placebos of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos of Ginkgo Leaf Tablets and Liuwei Dihuang Pills
Study: 2111658
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg
Study: 30887717
Drug: Ankle block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankle block with 8-10 mL of 0.25% bupivacaine before surgery (Group N)
Study: 30887717
Drug: No regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regional analgesic pretreatment (Group C)
Study: 20953877
Drug: Hemodilution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution therapy using automated erythrocytapheresis
Study: 20953877
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hemodilution therapy)
Study: 7954482
Drug: moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide 300 mg daily (increased to 400 mg if necessary)
Study: 10936477
Drug: Aspirin combined
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin combined with low, ineffective doses of warfarin
Study: 3901790
Drug: DHE/H5,000 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE/H5,000 (0.5 mg dihydroergotamine plus 5,000 IU heparin)
Study: 3901790
Drug: DHE/H2,500 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE/H2,500 (0.5 mg dihydroergotamine plus 2,500 IU heparin)
Study: 3901790
Drug: H5,000 (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5,000 (5,000 IU heparin alone)
Study: 3901790
Drug: DHE (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE (0.5 mg dihydroergotamine alone)
Study: 12747810
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg per day
Study: 11480539
Drug: Cisapride (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (7.5 mg)
Study: 9602871
Drug: Calcipotriol dilution
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol dilution series (range 0.016-250 micrograms/mL)
Study: 9602871
Drug: Calcipotriol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 2 micrograms/mL citrate-buffered isopropanol solution applied under occlusion for 48 h using small Finn Chambers
Study: 2810183
Drug: IV combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV combination of cefuroxime and metronidazole
Study: 31739839
Drug: Donafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib 200 mg bid
Study: 19955882
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no meditation treatment)
Study: 11230785
Drug: Hormone-replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-replacement therapy (HRT) with conjugated equine estrogen and medroxyprogesterone acetate for 6 months
Study: 9669827
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg twice daily via the Diskus/Accuhaler inhaler (D/A)
Study: 3310905
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metoclopramide and dexamethasone
Study: 8000726
Drug: Combination antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiemetic regimens (5‐HT3 antagonist, dexamethasone, benzodiazepine)
Study: 2834929
Drug: Flunitrazepam (Rohypnol)
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (Rohypnol) 0.03 mg/kg body weight
Study: 31686093
Drug: NPT088 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NPT088 treatment for 6 months
Study: 6352281
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg b.d.
Study: 23445141
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg o.d.
Study: 15097035
Drug: Once-daily omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily omeprazole (1 x 20 mg)
Study: 15097035
Drug: Twice-daily omeprazole
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily omeprazole (2 x 20 mg)
Study: 11147927
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg, up to 150 mg)
Study: 8468314
Drug: Adinazolam sustained
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam sustained release, N = 89, treatment duration 4 weeks
Study: 26432571
Drug: Continue statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue statin medications
Study: 26432571
Drug: Discontinue statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue statin medications
Study: 24872333
Drug: Ceftiofur crystalline‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftiofur crystalline‐free acid (CCFA) administered to all steers in a pen
Study: 12699020
Drug: Standard parent-child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parent-child interaction therapy (PCIT; STD)
Study: 12699020
Drug: Modified PCIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified PCIT (abbreviated treatment)
Study: 11397498
Drug: Active participation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active participation of mothers during speech therapy sessions
Study: 30785829
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus low-dose ipilimumab
Study: 28333093
Drug: 80 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g/day dry-cured pork ham
Study: 24130005
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + Alagebrium (200 mg/d)
Study: 24130005
Drug: Sedentary +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedentary + Alagebrium (200 mg/d)
Study: 19938212
Drug: Real intradermal
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real intradermal acupuncture (RA group)
Study: 18855801
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg
Study: 8956394
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ketorolac added to the lidocaine used for IVRA
Study: 8956394
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ketorolac added to the lidocaine used for wound infiltration
Study: 8956394
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional medications)
Study: 1347237
Drug: MgSO4 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (30 mg/kg)
Study: 29934667
Drug: Tolvaptan (TLV)
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan (TLV) ≤ 15 mg/day
Study: 29934667
Drug: Furosemide (FUR)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (FUR) ≤ 40 mg/day
Study: 17039794
Drug: Batroxobin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batroxobin (0.5 ml, 2 BU/ml)
Study: 17039794
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/ml)
Study: 11641593
Drug: Lubeluzole (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole (7.5 mg i.v. over 1 h, then continuous 5‐day infusion of 10 mg/day)
Study: 9207368
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (10^7 or 10^9 cfu) in inpatient volunteers
Study: 9207368
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (10^8 or 10^9 cfu) in outpatient volunteers
Study: 9207368
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (all doses)
Study: 3625405
Drug: Intravenous medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous medication administration
Study: 3625405
Drug: Gravity-controlled infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gravity-controlled infusion device delivery
Study: 3625405
Drug: Potassium concentrations
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium concentrations less than or equal to 20 mEq/L
Study: 27434314
Drug: Oral paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral paliperidone extended-release (ER)
Study: 17290029
Drug: Pioglitazone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (titrated to 45 mg)
Study: 16084051
Drug: Conventional surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional surgery and systemic chemotherapy
Study: 8567827
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 5 mg mifepristone
Study: 8567827
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of 5 mg/day for 3 days (starting when leading follicle was 6-11 mm)
Study: 6159957
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment after palliative resection
Study: 25809828
Drug: VSL#3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 treatment
Study: 23328275
Drug: Empagliflozin 50
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 50 mg QD for 5 days
Study: 23328275
Drug: Empagliflozin 50
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 50 mg QD and Linagliptin 5 mg QD for 7 days
Study: 20416236
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care with sequential father testing (n=590)
Study: 20416236
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care with sequential testing
Study: 18983791
Drug: L-ornithine-L-aspartate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate (20 g/d)
Study: 15659079
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg, b.i.d.)
Study: 10321537
Drug: Ocular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular administration of 0.3 mg atropine
Study: 10321537
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and ocular administration of 0.3 mg atropine
Study: 30946150
Drug: Once-daily Atripla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Atripla
Study: 29855315
Drug: Bundled payment
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bundled payment program offering $5000 for the first year of localized breast cancer treatment
Study: 29855315
Drug: Bundled payment
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bundled payment program offering $15,000 for the first year of localized breast cancer treatment
Study: 29855315
Drug: Bundled payment
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bundled payment program offering $20,000 for the first year of localized breast cancer treatment
Study: 8606276
Drug: Prazosin and
Normalized name: prazosin and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin and placebo therapy
Study: 18976472
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine
Study: 27693898
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine
Study: 3912314
Drug: Pirenzepine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine, 50 mg three times a day for 6 weeks
Study: 3912314
Drug: Carbenoxolone, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone, 100 mg three times a day for one week followed by 50 mg three times a day for the remaining five weeks
Study: 19780243
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy after concurrent chemoradiotherapy
Study: 15514412
Drug: Placebo extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo extended treatment
Study: 15514412
Drug: Placebo brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo brief treatment
Study: 9475021
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.5% solution
Study: 10349190
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (200 micrograms)
Study: 2955980
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (200 micrograms) and inhaled ipratropium bromide (60 micrograms)
Study: 19345771
Drug: Constraint-Induced Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Therapy (CIT) for 10 consecutive weekdays, 6 hours a day, with trainer-supervised, functionally based activities using massed practice.
Study: 16989011
Drug: Flucloxacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin (2 g intravenous dose)
Study: 2931973
Drug: Copper gluconate
Normalized name: Copper Gluconate
DrugBank: Copper gluconate (DB11246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper gluconate (10 mg/day)
Study: 17360077
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS)
Study: 23269596
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg orally every 12 hours for 24 weeks
Study: 18615666
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g calcium
Study: 18615666
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 g calcium and 2,000 IU vitamin D(3)
Study: 8175117
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d.
Study: 8175117
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg b.i.d.
Study: 8520158
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution (group B)
Study: 1967562
Drug: Xamoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (0.2 mg/kg)
Study: 7002074
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) - total dose of 6.6 g over two weeks
Study: 7002074
Drug: Metrifonate -
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate - one dose of 10 mg/kg body weight at ten-day intervals, three times
Study: 23437972
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 μg/g plus betamethasone 0.5 mg/g (Daivobet® Gel)
Study: 29643323
Drug: linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin (5 mg once daily)
Study: 11402631
Drug: Intravenous tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tacrolimus 0.020 mg/kg IBW over 4 hours
Study: 11402631
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus approximately 0.12 mg/kg IBW
Study: 9768401
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of aspirin intake (Group A)
Study: 3292105
Drug: Pinacidil (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (12.5 to 75 mg b.i.d.)
Study: 3292105
Drug: Prazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1 to 10 mg b.i.d.)
Study: 348532
Drug: Diflunisal 500
Normalized name: diflunisal 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 500 mg
Study: 6348714
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg
Study: 348532
Drug: Diflunisal 125
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal 125 mg
Study: 348532
Drug: Diflunisal 250
Normalized name: diflunisal 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 250 mg
Study: 26400458
Drug: Vercirnon 500
Normalized name: Vercirnon
DrugBank: Vercirnon (DB15250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vercirnon 500 mg twice daily
Study: 26400458
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (placebo, once daily, twice daily)
Study: 7877117
Drug: Trimipramine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine monotherapy
Study: 19038406
Drug: Amitriptyline and
Normalized name: amitriptyline and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline and haloperidol combination
Study: 17307427
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 to 60 mg, n = 177
Study: 17307427
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 to 60 mg